https://orcid.org/0000-0003-4886-9007
References
- Ma J, Sehgal NL, Ayanian JZ, et al. National trends in statin use by coronary heart disease risk category. PLoS Med. 2005;2(5):e123.
- Christopher-Stine L. Statin myopathy: an update. Curr Opin Rheumatol. 2006;18(6):647–653.
- Kapur NK, Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag. 2008;4(2):341–353.
- Selva-O'Callaghan A, Alvarado-Cardenas M, Pinal-Fernández I, et al. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Rev Clin Immunol. 2018;14(3):215–224.
- Albayda J, Christopher-Stine L. Identifying statin-associated autoimmune necrotizing myopathy. Cleve Clin J Med. 2014;81(12):736–741.
- Christopher-Stine L, Casciola-Rosen LA, Hong G, et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62(9):2757–2766.
- Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713–721.
- Needham M, Fabian V, Knezevic W, et al. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord. 2007;17(2):194–200.
- Milone M. Diagnosis and management of immune-mediated myopathies. Mayo Clin Proc. 2017;92(5):826–837.
- Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016;374(7):664–669.
- Christopher-Stine L, Basharat P. Statin-associated immune-mediated myopathy: biology and clinical implications. Curr Opin Lipidol. 2017;28(2):186–192.
- Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol. 2011;7(6):349–359.
- Danieli MG, Pettinari L, Moretti R, et al. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev. 2011;10(3):144–149.
- Mammen AL, Tiniakou E. Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med. 2015;373(17):1680–1682.
- Thornby KA, Henneman A, Brown DA. Evidence-based strategies to reduce intravenous immunoglobulin-induced headaches. Ann Pharmacother. 2015;49(6):715–726.
- Ness S. Differentiating characteristics and evaluating intravenous and subcutaneous immunoglobulin. Am J Manag Care. 2019;25(6 Suppl):S98–S104.
- Jolles S, Sleasman JW. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach. Adv Ther. 2011;28(7):521–533.
- Patrick C, Jean-Christophe D, Jean-Charles C, et al. High-dose subcutaneous immunoglobulins for the treatment of severe treatment-resistant polymyositis. Case Rep Rheumatol. 2014;2014:458231.